Evidence map›Paper›PMID 29284197›Full record

ArticleAddiction (Abingdon, England)2018

The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys.

Louisa Degenhardt, Sukanta Saha, Carmen C W Lim, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Laura H Andrade, Evelyn J Bromet, Ronny Bruffaerts, José Miguel Caldas-de-Almeida and 23 more

Open access · bronzeAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 21 countries.

Louisa DegenhardtNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW.ORCID 0000-0002-8513-2218
Sukanta SahaQueensland Centre for Mental Health Research, and Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.
Carmen C W LimQueensland Centre for Mental Health Research, and Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia.
Sergio Aguilar-GaxiolaCenter for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA.
Ali Al-HamzawiCollege of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq.
Jordi AlonsoHealth Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.
Laura H AndradeNúcleo de Epidemiologia Psiquiátrica-LIM 23, Instituto de Psiquiatria Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Evelyn J BrometDepartment of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA.
Ronny BruffaertsUniversitair Psychiatrisch Centrum, Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium.
José Miguel Caldas-de-AlmeidaLisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
Giovanni de GirolamoUnit of Epidemiological and Evaluation Psychiatry, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)-St John of God Clinical Research Centre, Brescia, Italy.
Silvia FlorescuNational School of Public Health, Management and Professional Development, Bucharest, Romania.
Oye GurejeDepartment of Psychiatry, University College Hospital, Ibadan, Nigeria.
Josep M HaroParc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
Elie G KaramDepartment of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon.
Georges KaramDepartment of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon.
Viviane Kovess-MasfetyEHESP Dpt MéTis Epidémiologie et biostatistiques pour la décision en santé publique /Laboratoire Psychopathologie et Processus de Santé (EA 4057), Université Paris Descartes EHESP School for Public Health, Paris, France.
Sing LeeDepartment of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.
Jean-Pierre LepineHôpital Lariboisière-Fernand Widal, Assistance Publique Hôpitaux de Paris, Universités Paris Descartes-Paris Diderot, Paris, France.
Victor MakanjuolaDepartment of Psychiatry, University College Hospital, Ibadan, Nigeria.
Maria E Medina-MoraNational Institute of Psychiatry Ramón de la Fuente, Mexico City, México.
Zeina MneimnehSurvey Research Center, University of Michigan, Ann Arbor, MI, USA.
Fernando Navarro-MateuUDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud. IMIB-Arrixaca, CIBERESP-Murcia, Murcia, Spain.
Marina PiazzaUniversidad Cayetano Heredia, Lima, Peru.
José Posada-VillaFaculty of Social Sciences, Colegio Mayor de Cundinamarca University, Bogota, Colombia.
Nancy A SampsonDepartment of Health Care Policy, Harvard Medical School, Boston, MA, USA.
Kate M ScottDepartment of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand.
Juan Carlos StagnaroDepartamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Margreet Ten HaveTrimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands.
Kenneth S KendlerDepartment of Psychiatry, Virginia Commonwealth University, Virginia, USA.
Ronald C KesslerDepartment of Health Care Policy, Harvard Medical School, Boston, MA, USA.
John J McGrathQueensland Centre for Mental Health Research, and Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-4792-6068
WHO World Mental Health Survey Collaborators
The University of Queensland · AUHarvard University · USUniversity College Hospital, Ibadan · NGUniversity of Balamand · LBChinese University of Hong Kong · HKDélégation Paris 5 · FRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz · MXIstituti di Ricovero e Cura a Carattere Scientifico · ITNational School of Public Health, Management and Professional Development · ROParc Sanitari Sant Joan de Déu · ESServicio Murciano de Salud · ESStony Brook School · USTrimbos Institute · NLUC Davis Health · USUniversidad Colegio Mayor de Cundinamarca · COUniversidad de Buenos Aires · ARUniversidade Nova de Lisboa · PTUniversidad Peruana Cayetano Heredia · PEUniversitair Ziekenhuis Leuven · BE

Funding

EPIDEMIOLOGY-- NATIONAL COMORBIDITY SURVEY REPLICATIONU01MH060220 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 1999 to 2010
$18.7M
Risk Factors for Psychopathology in the WHO WMH SurveysR01MH070884 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2005 to 2009
$6.0M
Social Role Disability and Mental-Physical Co-MorbidityR01MH069864 · NIMH · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI VON KORFF, MICHAEL R · 2004 to 2007
$2.2M
CROSS-NATIONAL STUDIES OF DRUG INVOLVEMENT: WMH2000R01DA016558 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2008
$1.7M
Drug Dependence Epidemiology and EnviromicsK05DA015799 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2015
$1.4M
World Mental Health Consortium Annual Meeting 2003-07R13MH066849 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HEERINGA, STEVEN G · 2003 to 2007
$735k
Lebanon-Epidemiology: The NCS Replication StudyR03TW006481 · FIC · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2004 to 2006
$142k
FIC NIH HHS R03 TW006481NIDA NIH HHS K05 DA015799NIDA NIH HHS R01 DA016558NIMH NIH HHS R01 MH069864NIMH NIH HHS R01 MH070884NIMH NIH HHS R13 MH066849NIMH NIH HHS U01 MH060220
6 · The paper itself

Abstract

BACKGROUND AND

aimsPrior research has found bidirectional associations between psychotic experiences (PEs) and selected substance use disorders. We aimed to extend this research by examining the bidirectional association between PEs and various types of substance use (SU) and substance use disorders (SUDs), and the influence of antecedent mental disorders on these associations. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We used data from the World Health Organization World Mental Health surveys. A total of 30 902 adult respondents across 18 countries were assessed for (a) six types of life-time PEs, (b) a range of types of SU and DSM-IV SUDs and (c) mental disorders using the Composite International Diagnostic Interview. Discrete-time survival analyses based on retrospective age-at-onset reports examined the bidirectional associations between PEs and SU/SUDs controlling for antecedent mental disorders.

findingsAfter adjusting for demographics, comorbid SU/SUDs and antecedent mental disorders, those with prior alcohol use disorders [odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.2-2.0], extra-medical prescription drug use (OR = 1.5, 95% CI = 1.1-1.9), alcohol use (OR = 1.4, 95% CI = 1.1-1.7) and tobacco use (OR = 1.3, 95% CI = 1.0-1.8) had increased odds of subsequent first onset of PEs. In contrast, those with temporally prior PEs had increased odds of subsequent onset of tobacco use (OR = 1.5, 95% CI = 1.2-1.9), alcohol use (OR = 1.3, 95% CI = 1.1-1.6) or cannabis use (OR = 1.3, 95% CI = 1.0-1.5) as well as of all substance use disorders (ORs ranged between 1.4 and 1.5). There was a dose response relationship between both count and frequency of PEs and increased subsequent odds of selected SU/SUDs.

conclusionsAssociations between psychotic experiences (PEs) and substance use/substance use disorders (SU/SUDs) are often bidirectional, but not all types of SU/SUDs are associated with PEs. These findings suggest that it is important to be aware of the presence of PEs within those with SUDs or at risk of SUDs, given the plausibility that they may each impact upon the other.

Indexed as

AdolescentAdultAgedAged, 80 and overDelusionsFemaleHallucinationsHumansMaleMarijuana UseMiddle AgedPsychotic DisordersSubstance-Related DisordersTobacco UseYoung AdultAlcoholcannabismental disordernicotineprescription drugpsychotic experiencessubstance abuse disordersubstance dependence disordersubstance usetobacco

Identifiers

PMID29284197
PMCPMC5895500
OpenAlexW2780438462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.